We serve Chemical Name:4-tert-butyl-calix[4]arene-crown-4-complex CAS:171058-95-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![4-tert-butyl-calix[4]arene-crown-4-complex](https://a.dearchem.com/CAS2/171058-95-0.png)
Chemical Name:4-tert-butyl-calix[4]arene-crown-4-complex
CAS.NO:171058-95-0
Synonyms:4-TERT-BUTYLCALIX(4)-CROWN-4;5,11,17,23-Tetrakis(1,1-dimethyl)-25,26-dihydroxy-27,28-crown-4-calix[4]arene;25,27-(3,6-dioxaocta-1,8-diyl)oxy-26,28-dihydroxy-5,11,17,23-tetra-tert-butyl-calix[4]arene;5,11,17,23-Tetrakis(1,1-dimethylethyl)-25,27-(crown-4)-26,28-dihydroxycalix[4]arene;p-t-butylcalix[4]crown-4;MFCD02093902;p-tert-butylcalix[4]crown-4
Molecular Formula:C40H48O4
Molecular Weight:592.80700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:766.4ºC at 760 mmHg
Density:1.069g/cm3
Index of Refraction:1.548
PSA:36.92000
Exact Mass:592.35500
LogP:7.72710
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-TERT-BUTYLCALIX(4)-CROWN-4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-tert-butylcalix[4]crown-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-tert-butylcalix[4]crown-4 Use and application,25,27-(3,6-dioxaocta-1,8-diyl)oxy-26,28-dihydroxy-5,11,17,23-tetra-tert-butyl-calix[4]arene technical grade,usp/ep/jp grade.
Related News: Amanpour is based in London, and said she feels fortunate to have health insurance through work and incredible doctors who are treating me in a country underpinned by, of course, the brilliant NHS [National Health Service],” CNN reported.
“I want to applaud Christiane Amanpour for her candor, bravery and always working towards the greater good,” he said in a statement. “As a cancer survivor, I too encourage people to listen to their bodies and get all early cancer screenings available to them. 4-tert-butyl-calix[4]arene-crown-4-complex manufacturer Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday. 4-tert-butyl-calix[4]arene-crown-4-complex supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 4-tert-butyl-calix[4]arene-crown-4-complex vendor “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” 4-tert-butyl-calix[4]arene-crown-4-complex factory Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.
“I want to applaud Christiane Amanpour for her candor, bravery and always working towards the greater good,” he said in a statement. “As a cancer survivor, I too encourage people to listen to their bodies and get all early cancer screenings available to them. 4-tert-butyl-calix[4]arene-crown-4-complex manufacturer Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday. 4-tert-butyl-calix[4]arene-crown-4-complex supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 4-tert-butyl-calix[4]arene-crown-4-complex vendor “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” 4-tert-butyl-calix[4]arene-crown-4-complex factory Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.
